KURA (Kura Oncology, Inc.) Stock Financials & Earnings | Market Cap Arena

KURA (Kura Oncology, Inc.) Stock Financials & Earnings | Market Cap Arena

KURAKura Oncology, Inc.

Mkt Cap$815M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$67M

Net Income (TTM)-$279M

EPS (TTM)-$3.18

Free Cash Flow (TTM)-$71M

Gross Margin94.6%

Op. Margin-449.9%

Net Margin-412.9%

FCF Margin-104.8%

P/S Ratio (TTM)12.1x

P/E Ratio (TTM)—

YoY Rev Growth+25.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$37M
Q2 23	$0	$0	-$40M
Q3 23	$0	-$216K	-$42M
Q4 23	$0	-$214K	-$47M
Q1 24	$0	-$234K	-$54M
Q2 24	$0	-$202K	-$56M
Q3 24	$0	$0	-$60M
Q4 24	$54M	$54M	-$22M
Q1 25	$14M	$14M	-$65M
Q2 25	$15M	$15M	-$73M
Q3 25	$21M	$18M	-$80M
Q4 25	$17M	$17M	-$86M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	15.1x	—
Q1 25	12.0x	—
Q2 25	9.8x	—
Q3 25	7.8x	—
Q4 25	12.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$36M	-$36M
Q2 23	-$26M	-$26M
Q3 23	-$29M	-$29M
Q4 23	-$34M	-$34M
Q1 24	-$49M	-$49M
Q2 24	-$43M	-$43M
Q3 24	-$43M	-$43M
Q4 24	$269M	$269M
Q1 25	-$72M	-$72M
Q2 25	-$29M	-$30M
Q3 25	-$81M	-$83M
Q4 25	$117M	$115M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$36K
Q2 23	$96K
Q3 23	$20K
Q4 23	$16K
Q1 24	$84K
Q2 24	$16K
Q3 24	$0
Q4 24	$372K
Q1 25	$292K
Q2 25	$1M
Q3 25	$3M
Q4 25	$2M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+11.5%
Q2 23	—	+13.2%
Q3 23	—	+16.1%
Q4 23	—	+33.0%
Q1 24	—	+48.9%
Q2 24	—	+41.0%
Q3 24	—	+41.0%
Q4 24	—	+63.2%
Q1 25	—	+44.7%
Q2 25	—	+55.9%
Q3 25	—	+68.2%
Q4 25	-67.8%	+35.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$7M	—
Q2 23	$7M	—
Q3 23	$7M	—
Q4 23	$7M	—
Q1 24	$9M	—
Q2 24	$8M	—
Q3 24	$8M	—
Q4 24	$9M	16.0%
Q1 25	$8M	55.6%
Q2 25	$7M	45.5%
Q3 25	$11M	52.8%
Q4 25	$11M	65.5%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$25M	$11M	—
Q2 23	$28M	$12M	—
Q3 23	$29M	—	$13M
Q4 23	$33M	—	$14M
Q1 24	$36M	$18M	—
Q2 24	$40M	$17M	—
Q3 24	$42M	$18M	—
Q4 24	$52M	$24M	—
Q1 25	$56M	$23M	—
Q2 25	$63M	$25M	—
Q3 25	$68M	$33M	—
Q4 25	$64M	—	$39M

Revenue Segments

Quarter	Operating Segments
Q2 25	$15M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$27M	$379M	$406M
Q2 23	$49M	$428M	$477M
Q3 23	$29M	$424M	$453M
Q4 23	$37M	$387M	$424M
Q1 24	$42M	$486M	$527M
Q2 24	$45M	$446M	$492M
Q3 24	$49M	$406M	$455M
Q4 24	$224M	$503M	$727M
Q1 25	$51M	$607M	$658M
Q2 25	$82M	$549M	$631M
Q3 25	$95M	$454M	$550M
Q4 25	$149M	$518M	$667M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	68M	+0.9%
Q2 23	70M	+2.0%
Q3 23	77M	+10.7%
Q4 23	77M	+0.1%
Q1 24	84M	+8.5%
Q2 24	87M	+3.3%
Q3 24	87M	+0.4%
Q4 24	87M	+0.2%
Q1 25	87M	+0.3%
Q2 25	88M	+0.2%
Q3 25	88M	+0.1%
Q4 25	88M	+0.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	$0	21
FY 16	$0	22
FY 17	$0	31
FY 18	$0	43
FY 19	$0	60
FY 20	$0	89
FY 21	$0	121
FY 22	$0	133
FY 23	$0	142
FY 24	$281K	192
FY 25	$260K	260